Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Alphav integrins lead the way for colorectal metastases.

McCarty JH.

Clin Cancer Res. 2008 Oct 15;14(20):6351-3. doi: 10.1158/1078-0432.CCR-08-1847.

2.

Preoperative evaluation of pancreatic adenocarcinoma.

Parsons CM, Sutcliffe JL, Bold RJ.

J Hepatobiliary Pancreat Surg. 2008;15(4):429-35. doi: 10.1007/s00534-007-1240-7. Epub 2008 Aug 1. Review.

PMID:
18670846
3.

Absence of alphavbeta6 integrin is linked to initiation and progression of periodontal disease.

Ghannad F, Nica D, Fulle MI, Grenier D, Putnins EE, Johnston S, Eslami A, Koivisto L, Jiang G, McKee MD, Häkkinen L, Larjava H.

Am J Pathol. 2008 May;172(5):1271-86. doi: 10.2353/ajpath.2008.071068. Epub 2008 Apr 1.

4.

Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.

Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage DJ, Kelly R, Heaney G, Rayhorn P, Reid C, Simon KJ, Horan GS, Tao N, Gardner HA, Skelly MM, Gown AM, Thomas GJ, Weinreb PH, Fawell SE, Violette SM.

Cancer Res. 2008 Jan 15;68(2):561-70. doi: 10.1158/0008-5472.CAN-07-2307.

5.

Alpha-v integrins as therapeutic targets in oncology.

Nemeth JA, Nakada MT, Trikha M, Lang Z, Gordon MS, Jayson GC, Corringham R, Prabhakar U, Davis HM, Beckman RA.

Cancer Invest. 2007 Oct;25(7):632-46. Review.

PMID:
18027153
6.

Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma.

Zhang ZY, Xu KS, Wang JS, Yang GY, Wang W, Wang JY, Niu WB, Liu EY, Mi YT, Niu J.

Clin Oncol (R Coll Radiol). 2008 Feb;20(1):61-6. Epub 2007 Nov 5.

PMID:
17981018
8.

A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer.

Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, Wistuba II, Roth JA, McGuire MJ, Brown KC.

Cancer Res. 2007 Jun 15;67(12):5889-95.

9.

Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival.

Hazelbag S, Kenter GG, Gorter A, Dreef EJ, Koopman LA, Violette SM, Weinreb PH, Fleuren GJ.

J Pathol. 2007 Jul;212(3):316-24.

PMID:
17503414
10.

Identification of pancreatic cancer stem cells.

Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM.

Cancer Res. 2007 Feb 1;67(3):1030-7.

11.

PET/CT: form and function.

Blodgett TM, Meltzer CC, Townsend DW.

Radiology. 2007 Feb;242(2):360-85. Review.

PMID:
17255408
12.

Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.

Czernin J, Allen-Auerbach M, Schelbert HR.

J Nucl Med. 2007 Jan;48 Suppl 1:78S-88S. Review.

13.

Screening for cancer with PET and PET/CT: potential and limitations.

Schöder H, Gönen M.

J Nucl Med. 2007 Jan;48 Suppl 1:4S-18S. Review.

14.
15.

Alphavbeta6 integrin in wound healing and cancer of the oral cavity.

Thomas GJ, Nyström ML, Marshall JF.

J Oral Pathol Med. 2006 Jan;35(1):1-10. Review.

PMID:
16393247
16.

Integrin-mediated activation of latent transforming growth factor beta.

Sheppard D.

Cancer Metastasis Rev. 2005 Sep;24(3):395-402. Review.

PMID:
16258727
17.

Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients.

Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M.

J Nucl Med. 2005 Aug;46(8):1333-41.

18.

Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness.

Heinrich S, Goerres GW, Schäfer M, Sagmeister M, Bauerfeind P, Pestalozzi BC, Hany TF, von Schulthess GK, Clavien PA.

Ann Surg. 2005 Aug;242(2):235-43.

19.

Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment.

Delbeke D, Pinson CW.

J Hepatobiliary Pancreat Surg. 2004;11(1):4-10. Review.

PMID:
15747028
20.

Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma.

Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P, Mercurio AM.

J Clin Invest. 2005 Feb;115(2):339-47.

Supplemental Content

Support Center